Business
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun R. Bagai, Chief Executive Officer, will present at the Aegis Capital Virtual Conference being held on May 7-9, 2024.\n\n\nMr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in which RenovoRx raised $17.2 million in total gross proceeds. The financing provides RenovoRx sufficient funding to advance pivotal Phase III TIGeR-PaC clinical trial, expand development pipeline into additional cancer indications and continue the company’s ongoing exploration of new commercial business development opportunities with its therapeutic technologies.\n\n\nThe TIGeR-PaC study is evaluating the Company’s lead product candidate, RenovoGem™, and proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer. The second interim analysis for TIGeR-PaC will be triggered by the 52nd event (death), which is estimated to occur in late 2024.\n\n\nAegis Capital Virtual Conference:\nDate: May 9, 2024\nTime: 10:30 a.m. ET – 10:55 a.m. ET\nSpeaker: Shaun Bagai, CEO\nWebcast: https://us02web.zoom.us/meeting/register/tZIkc-mvqjItHdXZp6x-w9XGPgV2CAfRuTqq#/registration\n\n\nTo schedule a one-on-one investor meeting with Mr. Bagai, please contact your Aegis Capital representative or KCSA Strategic Communications at [email protected].\n\n\nA replay of this presentation will be available for at least 30 days following the date of the presentation on the Company’s website at https://ir.renovorx.com/.\n\n\nAbout RenovoRx, Inc.\n\n\nRenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a proprietary local drug-delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted...